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Summary
Purpose: To investigate changes in levetiracetam (LEV) serum concentration/dose
ratio (C/D-ratio) in relation to pregnancy.
Methods: Altogether 21 consecutive pregnancies in 20 womenwith epilepsy receiving
LEV during gestation were studied retrospectively. The main target variable was the
C/D-ratio before and during pregnancy, and in the post partum period. Secondary
target variables were changes in LEV dose, concomitant use of other antiepileptic
drugs and seizure frequency. Student’s paired t-test and two-sample t-test for
independent samples were used to test for statistically significant changes in C/D-ratio
means.
Results: Mean C/D-ratio in the third trimester was 50% of the mean C/D-ratio at
baseline (p < 0.001, n = 11). Baseline levels were reached within the first weeks after
pregnancy. The interindividual variability was pronounced.
Conclusions: Serum concentrations of LEV declined significantly in the third trimester
of pregnancy and increased rapidly after delivery.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Levetiracetam (LEV) is a newer antiepileptic drug
(AED) with efficacy in various seizure types.1 Due to
its rapidly increasing use, a growing number of
women receive LEV during pregnancy. The volume* Corresponding author. Tel.: +47 92 01 93 55;
fax: +47 73 55 08 15.
E-mail address: andreas.westin@legemidler.no (A.A. Westin).
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doi:10.1016/j.seizure.2007.11.027of distribution of LEV is close to intra- and extra-
cellular water and the protein binding is minimal.
The major metabolic pathway (applying to 24% of an
administered dose) is extrahepatic hydrolysis of the
acetamide group. Most of the drug is excreted
unchanged by the kidneys.2
A range of pharmacokinetic alterations may result
from the pregnant state. Some important factors are
changes inplasmavolumeandvolumeofdistribution,
altered drug protein binding, changes in metabolic. Published by Elsevier Ltd. All rights reserved.
Serum concentration/dose ratio of levetiracetam 193capacity as well as increased renal blood flow with
enhanced glomerular filtration rate.3,4 While gesta-
tion-related factors are known to influence the phar-
macokinetic properties of older generation AEDs,4,5
relatively little is known about their impact on the
newer AEDs, with the exception of lamotrigine,
which has been extensively studied (for an overview,
see Tomson and Battino4). A marked increase in
apparent clearance has been demonstrated for lamo-
trigine. A similar finding has been made for the
monohydroxy derivative of oxcarbazepine.6,7
Limited data on the pharmacokinetics of LEV
during pregnancy has so far been reported. Two
case series, of which one only has been presented
as an abstract, suggest that the apparent clearance
of LEV also increases.8,9 This increase appears to be
higher than can be accounted for by enhanced renal
blood flow alone.9
The objective of the present study was to confirm
the previously published results, and to provide
further information on the course of the maternal
LEV serum concentration/dose ratio (C/D-ratio)
throughout pregnancy and the post partum period.
Additionally, we aimed to gather information on
the pattern of seizure control in pregnant women
using LEV.Material and methods
Women from two Norwegian epilepsy outpatient
clinics, participating in the European antiepileptic
drug and pregnancy registry (EURAP) were screened
for the use of LEV. Altogether 21 consecutive preg-
nancies in 20 women were identified. Nineteen of
the pregnancies were completed; spontaneous
abortions occurred in two. Mean age at time of
delivery was 29 years (range: 21—38 years). Data
on drug use and dosage, seizure frequency, seizure
type and the occurrence of status epilepticus were
obtained prospectively at each trimester according
to the EURAP protocol.10 Seizures were recorded by
patient diaries. Supplementary clinical and pharma-
cological data were retrospectively collected from
themedical records of each subject. LEV was used in
monotherapy in five pregnancies, and in combina-
tion with other AEDs in the remaining 16. Treatment
characteristics (maximum doses in each trimester)
are summarized in Table 1.
Blood samples were taken drug fasting (10—14 h
after last dose) at different stages prior to, during
and after gestation in 19 pregnancies. They were
analyzed with a liquid chromatography—mass spec-
trometry (LC—MS) method. Levetiracetam was
extracted from 100 mL serum with 500 mL dichlor-
ometane:isopropanol (90:10) after addition of inter-nal standard solution (d6-levetiracetam). After
mixing and centrifugation the organic extract was
evaporated to dryness with air, the residue was
reconstituted in 100 mL acetonitrile, transferred
to vials and injected on an Agilent MSD 1100 LC—
MS system (Agilent, Palo Alto, CA). The LC—MS
system consisted of a G1379A degasser, a G1311A
quaternary pump, a G1313A autosampler, a G1316A
column oven and a G1946A mass spectrometer.
Separation was performed on a Zorbax XDB-C8
(150 mm  4.6 mm) column with a mobile phase
consisting of acetonitrile:formic acid 55:45. Leve-
tiracetamwasmonitored after positive electrospray
ionization at m/z 171.1, the internal standard d6-
levetiracetam atm/z 132.1. The calibrated range of
the method was from 5 to 500 mM. Six quality con-
trol samples covering the range from 25 to 250 mM
were analyzed with every batch of unknown sam-
ples. Between-day relative standard deviation cal-
culated from quality control samples was better
than 16.9% at 25 mM and 7.7% at 250 mM. The limit
of quantification of the method was 5 mM.
Informed consent was given by all patients.
The serum concentration/dose ratio (C/D-ratio)
was used as the primary outcome measure, as doses
were not kept constant during the study. The LEV C/
D-ratio was calculated by dividing the serum concen-
tration of LEV (expressed as mmol/L) by the total
daily dose (in mg). Thus, the LEV C/D-ratio expresses
the serum concentration per milligram LEV given.
The last sample prior to pregnancy, or (if missing) a
sample taken 2 or 4 weeks after pregnancy served as
the baseline value for each subject. Thus, the term
baseline refers to the non-pregnant state, which
might be either before or after pregnancy.Statistics
Results are presented as mean (SD) or median,
as appropriate, for each trimester and for the
baseline. Student’s paired t-test and independent
samples t-test were used to compare mean LEV
C/D-ratios in each trimester with the mean C/D-
ratios before and after pregnancy.
A p-value 0.05 was considered statistically
significant.Results
C/D-ratio during pregnancy
The box plot in Fig. 1 shows the median C/D-ratio at
each sampling time. It indicates a gradual decrease
throughout pregnancy, with an almost immediate
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Table 1 Treatment characteristics and clinical course during pregnancy
Patient
number
Antiepileptic
drug
Doses (mg/day) Seizures (3 months prior to
pregnancy and during
pregnancy
At
conception
First
trimester
Second
trimester
Third
trimester
1 Levetiracetam 1500 1500 1500 1500 SPS: 8—10/month
Carbamazepine 1200 1200 1200 1200
2 Levetiracetam 2000 2500 2500 2500 CPS: 1/month prior to pregnancy,
but none duringValproate 900 900 0 0
Lamotrigine 0 200 200 200
3 Levetiracetam 3000 3000 3000 3500 CPS: 1/month prior to pregnancy
and during the first trimesterCarbamazepine 1200 1200 1200 1200
SPS: Sporadic in the third trimester
4 Levetiracetam 0 0 1500 2000 None prior to pregnancy
Valproate 1800 1800 1800 1800 CPS: 8—10/month in the first
trimesterTopiramate 300 300 300 300
GTC: 2 in the second trimester,
4 in the third trimester
5 Levetiracetam 1500 1500 1500 2000 None prior to pregnancy
Myoclonic: 1/month in the
first trimester, 4/month in
the second, but none in the
third trimester
6 Levetiracetam 0 0 2000 2500 SPS: Daily prior to and
during pregnancy
Gabapentin 1200 1200 1200 1200
Lamotrigine 300 400 600 600
7 Levetiracetam 2000 2000 2000 2000 None prior to pregnancy
Lamotrigine 550 600 700 800 GTC: 1 in the first trimester,
2 in the second
CPS: Sporadic
8 Levetiracetam 2000 2500 2500 2500 None
Lamotrigine 150 300 300 400
9 Levetiracetam 1500 1500 1500 1500 None
10 Levetiracetam 500 1000 500 0 GTC: 1/month prior to and
during pregnancyOxcarbazepine 0 1200 2400 2400
CPS: Several prior to pregnancy
and during the first and second
trimester, less in third
Pregabaline 450 450 450 450
11 Levetiracetam 1500 1500 1500 1500 None
12aa Levetiracetam 1500 1500 n.a. n.a. GTC: One prior to pregnancy,
but none during first
trimesterLamotrigine 200 200
12b Levetiracetam 1500 1500 1500 2000 None prior to pregnancy
Lamotrigine 200 200 300 300 CPS: 1/month during the
third trimester
13 Levetiracetam 1750 1750 2500 2500 None prior to pregnancy
GTC: 1 in the third trimester
14 Levetiracetam 1500 1500 1500 1500 None
Valproate 900 1800 1800 1800
15 Levetiracetam 2500 2500 2500 2500 CPS: 1/week prior to and
during pregnancyLamotrigine 150 150 150 150
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Table 1 (Continued )
Patient
number
Antiepileptic
drug
Doses (mg/day) Seizures (3 months prior to
pregnancy and during
pregnancy
At
conception
First
trimester
Second
trimester
Third
trimester
16 Levetiracetam 1000 2000 2000 2000 None prior to pregnancy
Carbamazepine 500 500 400 800 GTC: 1/month in the first trimester
CPS: Increasing from weekly to
daily throughout pregnancy
17 Levetiracetam 2000 2000 2000 2000 CPS: 4/month prior to pregnancy and
during the first and second trimester,
2/month in the third trimester
Oxcarbazepine 1200 1200 1200 1200
18 Levetiracetam 1000 1000 1000 0 GTC: 1/month before and during the
first two trimestersTopiramate 200 200 200 200
Absences: Several prior to pregnancy
and during the first two trimesters,
rare in the third trimester
Valproate 1200 1200 1200 1200
19a Levetiracetam 1500 1500 n.a. n.a. None prior to or during first trimester
20 Levetiracetam 1500 1500 2000 2500 CPS: 1/week prior to and throughout
pregnancy
Topiramate 400 400 450 400 GTC: Several/month prior to
pregnancy, less than 1/month
in the first and second trimester,
weekly in the third trimester
Status epilepticus: Convulsive
in the second and non-convuslive
in the third trimester
a Spontaneous abortion in first trimester; n.a., not applicable; SPS, simple partial seizures; CPS, complex partial seizures; GTC,
generalized tonic-clonic seizures.increase after delivery. However, complete sets of
C/D-ratios, i.e. pre-pregnancy, all three trimesters,
and post-pregnancy values, were not available
from all patients (Table 2). In seven patients weFigure 1 Boxplot showing the serum concentration/
dose ratio [(mmol/L)/(mg/day)] of all samples prior to,
during and post pregnancy. Numbers of samples available
in each group are given at the bottom. Circles denominate
outliers.obtained sets from all trimesters and at baseline.
The mean C/D-ratio (SD) in these patients at
baseline was 0.036 (0.015). In all trimesters it
was lower than at baseline, although not signifi-
cantly lower in the first and second trimester. In
the third trimester, the mean C/D-ratio was 0.022
(0.010), which was significantly lower than at
baseline (p = 0.005, n = 7). In addition to these
seven patients, four patients provided blood sam-
ples from the third trimester and at baseline, but
not from the first and second trimester. The C/D-
ratio changes from baseline to the third trimester
in these altogether 11 patients (seven with com-
plete data from all trimesters plus four with third
trimester data only) are shown in Fig. 2. Among
these patients, the mean C/D-ratio (SD) in the
third trimester was 0.021 (0.009), that is signifi-
cantly lower than the baseline value of 0.042
(0.018) ( p < 0.001).
C/D-ratio after delivery
Blood samples were collected 3—5 days after birth
(n = 9), 2 weeks after birth (n = 8) and 4 weeks after
birth (n = 9) (some data previously reported by
Johannessen et al.11). The mean C/D-ratios at these
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Table 2 Serum concentration/dose ratio [(mmol/L)/(mg/day)] of levetiracetam during and after pregnancy
Patient
number
Prior to
pregnancy
First
trimester
Second
trimester
Third
trimester
3—5 days
after birth
2 weeks
after birth
4 weeks
after birth
1 — — — — 0.025 0.027 0.039
2 — — — — 0.025 0.027 0.032
3 0.019 0.009 0.022 0.018 0.019 0.023 0.020
4 — — — — 0.035 — 0.022
5 — — — 0.020 0.015 0.037 —
6 — — — —— 0.034 0.036 0.068
7 0.032 0.023 0.024 0.020 — — 0.030
8 — 0.027 0.024 0.041 — — 0.064
9 0.077 0.034 — 0.030 — — —
10 0.094 0.036 — — —— — —
11 0.035 0.025 0.014 0.010 — — —
12a 0.048 0.028 n.a. n.a. n.a. n.a. n.a.
12b 0.048 0.027 0.021 0.029 — 0.032 —
13 0.054 — 0.016 0.015 — — 0.063
14 0.041 — — 0.013 — — —
15 — — — — — — —
16 0.029 0.023 0.021 0.014 0.027 0.036 —
17 0.030 — 0.019 — 0.038 — —
18 0.014 0.015 0.030 — — — —
19 — — n.a. n.a. n.a. n.a. n.a.
20 — 0.034 0.031 0.019 0.043 0.027 0.025
Mean 0.043 0.026 0.022 0.021 0.029 0.031 0.040
St. dev. 0.022 0.008 0.005 0.009 0.009 0.005 0.018
n.a., not applicable (spontaneous abortions).sampling times were compared to the 11 samples
from the third trimester using an independent sam-
ples t-test. The mean (SD) C/D-ratio was
0.031  0.005 (n = 8) 2 weeks after birth and
0.040  0.019 (n = 9) 4 weeks after birth. These
values were both significantly higher than the third
trimester value of 0.021  0.009 (n = 11; p = 0.02
and 0.01, respectively). There was a trend towards a
statistically significant difference already 3—5 daysFigure 2 Individual serum concentration/dose ratios
[(mmol/L)/(mg/day)] at baseline and during the third
trimester, in 11 women on levetiracetam.after birth (mean (SD) C/D-ratio was 0.29  0.009
(n = 9); p = 0.06).
Dose adjustments
In 11 pregnancies, the LEV dose was increased (in
two of them LEV therapy was started during preg-
nancy); four increments were performed in the first
trimester, four in the second and six in the third
trimester. In a total of 14 pregnancies, the dose of
either LEV or concomitant AEDs was increased at
least once (Table 1). AED dose increase was con-
ducted during the first trimester in seven, during the
second in six, and during the third trimester in 10
pregnancies. In two pregnancies, LEV was with-
drawn.
Seizure frequency
Increased seizure frequency was observed in seven
of the 19 completed pregnancies (Patients 4, 5, 7,
12, 13, 16, 20), in five of them during the third
trimester. Reduced seizure frequency was observed
in five (Patients 2, 3, 10, 17, 18); In the remaining
pregnancies, the subjects were either seizure free
prior to conception and throughout pregnancy, or
their seizure frequency remained stable during the
study period (Table 1). Among the seven patients
Serum concentration/dose ratio of levetiracetam 197with increased seizure frequency, five had an
increased number of generalized tonic-clonic sei-
zures. One (Patient 20) experienced an incident of
convulsive status epilepticus in the second trime-
ster, and of non-convulsive status epilepticus in the
third trimester, respectively. AED doses were
increased in all seven patients with increased sei-
zure frequency during pregnancy, and LEV was
increased in six of them. However, the observed
decline in LEV C/D-ratio was not more pronounced
in the patients with increased seizure ratio than in
the other subjects.Discussion
Our data show a significant decline of the maternal
LEV C/D-ratio in the third trimester, and a rapid
increase within the first 2 weeks post partum
(Table 2, Fig. 1). The drop of the C/D-ratio was
pronounced, with the mean value being reduced to
50% compared to baseline (n = 11). In other words,
on average a doubling of the LEV dose would be
required to maintain baseline serum concentrations
during the third trimester. However, as reflected by
Fig. 2 and Table 2, the extent of these changes shows
considerable intersubject variability. An accurate
prediction of the course of the LEV serum concen-
trations in pregnancy in individual patients is there-
fore not possible. Our findings are in accordance
with previous data on the impact of pregnancy on
the apparent clearance of LEV. In a conference
abstract, Pennell et al.8 reported a prospective
study of five pregnancies from the U.S., in which
blood samples were obtained in each trimester and
post partum. Serum concentrations were adjusted
for different dosage and for weight changes, by
calculating apparent LEV clearance [(dose/body
weight)/serum concentration]. Mean LEV clearance
in the third trimester was 154% of the baseline
value, indicating that in the third trimester about
1.5 times the original LEV dose would be needed to
keep serum concentrations at baseline levels. This
finding is supported by a recently published case
series from Sweden.9 In 12 pregnancies, it was found
that the apparent LEV clearance in the third trime-
ster was 342% of the baseline value, indicating a
need for an increase of the LEV dose of almost 3.5
times to keep serum concentrations unchanged.
Pennell’s, Tomson’s and our study suggest that the
dose-corrected serum levels of LEV during the third
trimester are between 29% and 65% of baseline
values, with the present findings close to the mean
(50%). However, neither the present nor the Swedish
study applies adjustments for body weight changes.
As suggested by Tomson et al.,9 this might partlyexplain the more prominent change in apparent LEV
clearance compared to the U.S. study.
Increased renal blood flow may contribute to the
observed decline in LEV serum concentrations dur-
ing pregnancy. The kidneys are the primary organ
responsible for the excretion of LEV, as 66% of an
administered LEV dose is found unchanged in the
urine.12 Since glomerular filtration rate increases
approximately 50% during pregnancy, renal LEV
clearance is likely to increase, but the extent is
unknown. Generally, the effect of pregnancy on
renal drug clearance is highly variable, ranging from
20% to 65% for most drugs.3 Another possible expla-
nation for the decline in LEV serum concentration
could be an increasedmetabolism during pregnancy.
The primary site for the hydrolysis of LEV appears to
be in the blood, and the metabolism does not
involve the hepatic cytochrome P450 (CYP) sys-
tem.12 However, enzyme-inducing AEDs have been
shown to decrease LEV serum concentrations by
about 20—30%.13,14 Thus, since LEV metabolism
appears to be inducible, it cannot be ruled out that
metabolic/endocrine changes during pregnancy
may induce LEV metabolism.
Whatever the mechanism, a change in LEV serum
concentrations of the foundmagnitude is likely to be
of clinical significance. In our study, an increase in
seizure frequency occurred in seven of 19 com-
pleted pregnancies; one patient had recurrent sta-
tus epilepticus. However, a clear correlation
between lowered LEV levels and seizure break-
through could not be demonstrated, conceivably
as LEV doses usually were increased as a response
to seizures, and because only two patients used LEV
as monotherapy. Nevertheless, similar observations
from the EURAP registry concerning seizure control
during pregnancy have recently been published.10
Among the enrolled women, two thirds had a stable
seizure frequency (the majority was seizure free),
whereas one third experienced a change, half of
them improved, the other half got worse. As
expected, incomplete seizure control appeared to
be associated with polytherapy and AED dose
changes.
In conclusion, our results confirm the findings of
earlier studies. We have shown that dose-corrected
LEV serum concentrations drop to about 50% of
baseline values in the third trimester of pregnancy,
and rapidly increase within the first weeks post
partum. Consequently, serial measurements of
LEV serum concentrations throughout pregnancy
and in the first weeks post partum are advisable,
particularly in patients with brittle seizure control.
A considerable number of women using LEV during
pregnancy may experience worsening of their sei-
zure frequency. The present findings are essential
198 A.A. Westin et al.for appropriate counselling and follow-up of women
who need treatment with LEV during pregnancy.Policy and ethics
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